4.6 Article

Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice

期刊

MOLECULAR CANCER THERAPEUTICS
卷 16, 期 2, 页码 376-387

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-16-0381

关键词

-

类别

资金

  1. NIH [CA93373]
  2. SBIR [HHSN261201000133C, HHSN261201200048C]
  3. LLNL [LDRD 08-LW-100]
  4. NIH/NIGMS [P41 RR13461]
  5. American Cancer Society
  6. Knapp Family Fund
  7. VA Career Development Award-2
  8. U.S. Department of Energy [DE-AC52-07NA27344]
  9. National Institutes of Health, National Center for Research Resources, Biomedical Technology Program [P41 RR13461]
  10. NCI [P30CA093373]

向作者/读者索取更多资源

We report progress on predicting tumor response to platinum-based chemotherapy with a novel mass spectrometry approach. Fourteen bladder cancer patients were administered one diagnostic microdose each of [14C] carboplatin (1% of the therapeutic dose). Carboplatin-DNA adducts were quantified by accelerator mass spectrometry in blood and tumor samples collected within 24 hours, and compared with subsequent chemotherapy response. Patients with the highest adduct levels were responders, but not all responders had high adduct levels. Four patient-derived bladder cancer xeno-graft mouse models were used to test the possibility that another drug in the regimen could cause a response. The mice were dosed with [14C] carboplatin or [14C] gemcitabine and the resulting drug-DNA adduct levels were compared with tumor response to chemotherapy. At least one of the drugs had to induce high drug-DNA adduct levels or create a synergistic increase in overall adducts to prompt a corresponding therapeutic response, demonstrating proof-ofprinciple for drug-DNA adducts as predictive biomarkers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据